The present disclosure provides, inter alia, methods and compositions (e.g., conjugates) for imaging, at high spatial resolution, targets of interest.

The invention relates to a new method of determining in a sample the presence or absence of one or more analyte members of a group of two or more analytes. The invention therefore relates to a multiplex assay for determining the presence or absence of each analyte in a group of multiple analytes. The assay uses aptamers and transmembrane pores.

The invention concerns novel streptavidin muteins. In one embodiment such a the mutein (a) contains at least two cysteine residues in the region of the amino acid positions 44 to 53 with reference to the amino acid sequence of wild type streptavidin as set forth at SEQ ID NO: 212 and (b) has a higher binding affinity than (i) a streptavidin mutein “1” (SEQ ID NO: 112) that comprises the amino acid sequence Val.sup.44-Thr.sup.45-Ala.sup.46-Arg.sup.47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).

A method of identifying a natural product comprising NP—[X].sub.n is provided. The method includes several steps. The first step includes selecting an organism having a biosynthetic pathway for producing the natural product comprising NP—[X].sub.n using a bioinformatics algorithm. The second step includes preparing a sample suspected to contain NP—[X].sub.n including a complex cellular metabolite mixture from an organism. The third step includes reacting the sample suspected to contain NP—[X].sub.n with reactivity probe Y according to Scheme I: Scheme I. NP—[X].sub.n represents a natural product NP having a chemical moiety X that is susceptible to chemical modification by reactivity probe Y to form at least one product adduct NP—[X].sub.n-m [Z].sub.n in which chemical moiety X reacts with reactivity probe Y to form adduct Z, wherein n ranges from 1 to about 10 and m is at least 1 and m≦n. The fourth step includes optionally dereplicating the product collection of at least one known labeled metabolite to provide a depleted product collection including at least one unknown labeled metabolite. The fifth step includes determining the structure of the at least one unknown labeled metabolite, thereby identifying the natural product comprising NP—[X].sub.n.

##STR00001##

Lanthanide chelate lipid nanoparticles, and methods of their synthesis and use are described. Biological molecules labeled with the lipid nanoparticles, useful in bioaffinity assays with improved sensitivities are also described.

A method for evaluating skin health is disclosed. The method can be used to select skin treatment regimens, ingredients and compositions.

The present disclosure relates to a solid phase coated with (strept)avidin and having attached thereto, by way of biotin:(strept)avidin interaction, a biotinylated first member of a binding pair, wherein the attached first member is capable of binding to a second member of the binding pair, but is not capable of binding to biotin or to (strept)avidin, and wherein no member of the binding pair is capable of hybridizing with a naturally-occurring single-stranded nucleic acid. The solid phase is particularly useful in immunoassays with samples having high content in biotin or (strept)avidin-binding derivatives thereof. The present disclosure further provides uses, kits and methods, particularly for determination of an analyte in a sample.

The present invention relates to a kit for predicting or diagnosing the degree of risk of disease, a method for providing information for predicting or diagnosing the degree of risk of disease, a method for screening a therapeutic agent of disease, and a pharmaceutical composition for prevention or treatment of disease, for nonalcoholic fatty liver disease. Specifically, through the kit for predicting or diagnosing of the present invention, the degree of risk of nonalcoholic fatty liver disease can be effectively predicted or diagnosed, and in particular, the predictive value and significance of information provision in non-obese subjects are excellent. Therefore, by providing effective information on nonalcoholic fatty liver disease through this, it can be effectively used to prevent or treat the corresponding disease. In addition, the pharmaceutical composition for prevention or treatment of the present invention may be effectively used for treatment of nonalcoholic fatty liver disease.

The present invention relates to a composition for preventing, alleviating or treating liver injury, for example, nonalcoholic fatty liver, and more specifically, it relates to a composition for preventing or treating liver injury comprising a Ruminococcus spp. strain.

The invention relates to a new method of determining in a sample the presence or absence of one or more analyte members of a group of two or more analytes. The invention therefore relates to a multiplex assay for determining the presence or absence of each analyte in a group of multiple analytes. The assay uses aptamers and transmembrane pores.